logo

Zogenix, Inc. (ZGNX)



Trade ZGNX now with
  Date
  Headline
12/17/2019 7:41:25 PM Zogenix : FINTEPLA Shows Dose-dependent Reduction In Convulsive Seizure Frequency In Dravet Syndrome Patients
11/25/2019 8:05:23 AM Zogenix Reports FDA Acceptance For Filing Of NDA, Priority Review For FINTEPLA
10/7/2019 8:05:54 AM Zogenix Subsidiary, Modis Therapeutics, Presents Positive Top-line Results From Pivotal Phase 2 RETRO Study
9/26/2019 7:16:08 AM Zogenix Resubmits New Drug Application For FINTEPLA
9/9/2019 8:13:20 AM Zogenix Completes Acquisition Of Modis Therapeutics
8/26/2019 7:09:51 AM Zogenix To Acquire Modis Therapeutics
6/27/2019 8:15:22 AM Zogenix Announces FDA Agreement To Proceed With Resubmission Of FINTEPLA NDA
2/6/2019 8:10:24 AM Zogenix Submits NDA To FDA And MAA To European Medicines Agency For FINTEPLA For Dravet Syndrome
12/3/2018 9:23:18 AM Zogenix Reports Positive Phase 3 Trial Results On Efficacy, Safety Of FINTEPLA In Dravet Syndrome
8/30/2018 8:17:12 AM Zogenix Reports New Data On Impact Of Dravet Syndrome And Other Epileptic Encephalopathies
8/6/2018 5:15:06 PM Zogenix Intends To Offer And Sell 6 Mln Shares In Public Offering
  
 
>